

Mari L Demarco

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9585766/publications.pdf>

Version: 2024-02-01

60
papers

2,170
citations

279798

23
h-index

233421

45
g-index

66
all docs

66
docs citations

66
times ranked

2973
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses. <i>Journal of Infectious Diseases</i> , 2023, 227, 838-849. | 4.0 | 31 |
| 2 | Proteoforms and their expanding role in laboratory medicine. <i>Practical Laboratory Medicine</i> , 2022, 28, e00260. | 1.3 | 15 |
| 3 | Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older Adults. <i>Journal of Infectious Diseases</i> , 2022, 225, 1129-1140. | 4.0 | 65 |
| 4 | Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy. <i>Npj Vaccines</i> , 2022, 7, 28. | 6.0 | 64 |
| 5 | Homotypic fibrillization of TMEM106B across diverse neurodegenerative diseases. <i>Cell</i> , 2022, 185, 1346-1355.e15. | 28.9 | 70 |
| 6 | Early increases in anti-SARS-CoV-2 antibody isotypes associated with organ dysfunction and mortality in patients hospitalized with COVID-19. <i>Intensive Care Medicine</i> , 2022, 48, 616-618. | 8.2 | 2 |
| 7 | Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , 2022, 18, 1868-1879. | 0.8 | 26 |
| 8 | Establishing pre-analytical requirements and maximizing peptide recovery in the analytical phase for mass spectrometric quantification of amyloid- β peptides 1-42 and 1-40 in CSF. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 198-206. | 2.3 | 2 |
| 9 | Aptamer-based enrichment of TDP-43 from human cells and tissues with quantification by HPLC-MS/MS. <i>Journal of Neuroscience Methods</i> , 2021, 363, 109344. | 2.5 | 5 |
| 10 | Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 7 |
| 11 | In IgG4 related disease, elevated IgG2 is an artifact not a biomarker. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, e8. | 3.4 | 2 |
| 12 | In Vitro Conversion Assays Diagnostic for Neurodegenerative Proteinopathies. <i>Journal of Applied Laboratory Medicine</i> , The, 2020, 5, 142-157. | 1.3 | 9 |
| 13 | An automated clinical mass spectrometric method for identification and quantification of variant and wild-type amyloid- β 1-40 and 1-42 peptides in CSF. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12036. | 2.4 | 5 |
| 14 | IgG4 plasma cell myeloma without clinical evidence of IgG4-related disease: a report of two cases. <i>Hematology</i> , 2020, 25, 335-340. | 1.5 | 10 |
| 15 | Alpha-1-antitrypsin molecular testing in Canada: A seven year, multi-centre comparison. <i>Clinical Biochemistry</i> , 2020, 81, 27-33. | 1.9 | 5 |
| 16 | Quantitative Profiling of Synuclein Species: Application to Transgenic Mouse Models of Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 613-621. | 2.8 | 3 |
| 17 | NullCanada: A novel α -1-antitrypsin allele with in cis variants Glu366Lys and Ile100Asn. <i>Clinical Biochemistry</i> , 2020, 79, 23-27. | 1.9 | 0 |
| 18 | Proteomic applications in pathology and laboratory medicine: Present state and future prospects. <i>Clinical Biochemistry</i> , 2020, 82, 12-20. | 1.9 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Applying the Alzheimer Disease ATN Diagnostic Framework in Atypical Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2020, 34, 357-359. | 1.3 | 3 |
| 20 | Detection and characterization of TDP-43 in human cells and tissues by multiple reaction monitoring mass spectrometry. <i>Clinical Mass Spectrometry</i> , 2019, 14, 66-73. | 1.9 | 7 |
| 21 | The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer's disease, frontotemporal dementia, and amyotrophic lateral sclerosis: A systematic review and meta-analysis. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 730-743. | 2.4 | 100 |
| 22 | A Rapidly Deteriorating Patient with Gross Increase in Serum Free Light Chains. <i>Clinical Chemistry</i> , 2019, 65, 1084-1088. | 3.2 | 0 |
| 23 | An Intact ACTH LC-MS/MS Assay as an Arbiter of Clinically Discordant Immunoassay Results. <i>Clinical Chemistry</i> , 2019, 65, 1397-1404. | 3.2 | 19 |
| 24 | MALDI-MS: Emerging roles in pathology and laboratory medicine. <i>Clinical Mass Spectrometry</i> , 2019, 13, 1-4. | 1.9 | 6 |
| 25 | <p>Phenotyping and outcomes of hospitalized COPD patients using rapid molecular diagnostics on sputum samples</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 311-319. | 2.3 | 7 |
| 26 | An automated mass spectrometric blood test for therapeutic drug monitoring of infliximab. <i>Clinical Mass Spectrometry</i> , 2019, 12, 16-22. | 1.9 | 7 |
| 27 | P4+ STRUCTURAL CHARACTERIZATION OF TDP+ IN HUMAN CELLS AND BRAIN TISSUE BY MULTIPLEàREACTIONàMONITORING MASS SPECTROMETRY. <i>Alzheimer's and Dementia</i> , 2019, 15, P1497. | 0.8 | 0 |
| 28 | Resolution of Spurious Immunonephelometric IgG Subclass Measurement Discrepancies by LC-MS/MS. <i>Clinical Chemistry</i> , 2018, 64, 735-742. | 3.2 | 36 |
| 29 | A Streamlined Method for Quantification of Apolipoprotein A1 in Human Plasma by LC-MS/MS. <i>Clinical Chemistry</i> , 2018, 64, 1782-1784. | 3.2 | 8 |
| 30 | Phenotyping COPD exacerbations using imaging and blood-based biomarkers. <i>International Journal of COPD</i> , 2018, Volume 13, 217-229. | 2.3 | 16 |
| 31 | At the Intersection of Proteomics and Big Data Science. <i>Clinical Chemistry</i> , 2017, 63, 1663-1663. | 3.2 | 2 |
| 32 | Manipulating trypsin digestion conditions to accelerate proteolysis and simplify digestion workflows in development of protein mass spectrometric assays for the clinical laboratory. <i>Clinical Mass Spectrometry</i> , 2017, 6, 1-12. | 1.9 | 25 |
| 33 | Amplification of Misfolded Prion Proteins in Blood and Cerebrospinal Fluid for Detection of CreutzfeldtàJakob Disease. <i>Clinical Chemistry</i> , 2017, 63, 1671-1673. | 3.2 | 2 |
| 34 | Biomarker Development in COPD. <i>Chest</i> , 2017, 151, 455-467. | 0.8 | 36 |
| 35 | C-reactive protein and N-terminal prohormone brain natriuretic peptide as biomarkers in acute exacerbations of COPD leading to hospitalizations. <i>PLoS ONE</i> , 2017, 12, e0174063. | 2.5 | 14 |
| 36 | The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2016, 2016, 1-7. | 1.9 | 12 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | P1192: Automated Mass Spectrometric Method for Identification and Quantitation of Wild-Type and Familial Variants of Amyloid- β Peptides in Cerebrospinal Fluid. <i>Alzheimer's and Dementia</i> , 2016, 12, P477. | 0.8 | 0 |
| 38 | Ready, Set, Type! Proteomics vs Agglutination for Escherichia coli H Antigen Confirmation. <i>Clinical Chemistry</i> , 2016, 62, 793-795. | 3.2 | 0 |
| 39 | Grave Clinicopathologic Correlation: A Case of Hyperthyroxinemia. <i>Journal of Applied Laboratory Medicine</i> , 2016, 1, 310-314. | 1.3 | 3 |
| 40 | Identifying Molecular Mechanisms of the Late-Phase Asthmatic Response by Integrating Cellular, Gene, and Metabolite Levels in Blood. <i>Annals of the American Thoracic Society</i> , 2016, 13, S98-S98. | 3.2 | 6 |
| 41 | Biomarker Development for Chronic Obstructive Pulmonary Disease. From Discovery to Clinical Implementation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 1162-1170. | 5.6 | 51 |
| 42 | Sweating the small stuff: Adequacy and accuracy in sweat chloride determination. <i>Clinical Biochemistry</i> , 2015, 48, 443-447. | 1.9 | 11 |
| 43 | Molecular Dynamics Simulations of Membrane- and Protein-Bound Glycolipids Using GLYCAM. <i>Methods in Molecular Biology</i> , 2015, 1273, 379-390. | 0.9 | 4 |
| 44 | Diafiltration MALDI-TOF Mass Spectrometry Method for Culture-Independent Detection and Identification of Pathogens Directly From Urine Specimens. <i>American Journal of Clinical Pathology</i> , 2014, 141, 204-212. | 0.7 | 69 |
| 45 | Renal Leukocyte Chemotactic Factor 2 (LECT2) Amyloidosis in First Nations People in Northern British Columbia, Canada: A Report of 4 Cases. <i>American Journal of Kidney Diseases</i> , 2014, 64, 790-792. | 1.9 | 18 |
| 46 | Beyond Identification. <i>Clinics in Laboratory Medicine</i> , 2013, 33, 611-628. | 1.4 | 50 |
| 47 | Three-Dimensional Structure of Glycolipids in Biological Membranes. <i>Biochemistry</i> , 2012, 51, 5725-5732. | 2.5 | 19 |
| 48 | From agonist to antagonist: Structure and dynamics of innate immune glycoprotein MD-2 upon recognition of variably acylated bacterial endotoxins. <i>Molecular Immunology</i> , 2011, 49, 124-133. | 2.2 | 37 |
| 49 | Presentation of Membrane-Anchored Glycosphingolipids Determined from Molecular Dynamics Simulations and NMR Paramagnetic Relaxation Rate Enhancement. <i>Journal of the American Chemical Society</i> , 2010, 132, 1334-1338. | 13.7 | 58 |
| 50 | Characterization of cell-surface prion protein relative to its recombinant analogue: insights from molecular dynamics simulations of diglycosylated, membrane-bound human prion protein. <i>Journal of Neurochemistry</i> , 2009, 109, 60-73. | 3.9 | 35 |
| 51 | Extension of the GLYCAM06 biomolecular force field to lipids, lipid bilayers and glycolipids. <i>Molecular Simulation</i> , 2008, 34, 349-364. | 2.0 | 93 |
| 52 | Structural glycobiology: A game of snakes and ladders. <i>Glycobiology</i> , 2008, 18, 426-440. | 2.5 | 130 |
| 53 | Atomic-resolution conformational analysis of the GM3 ganglioside in a lipid bilayer and its implications for ganglioside-protein recognition at membrane surfaces. <i>Glycobiology</i> , 2008, 19, 344-355. | 2.5 | 62 |
| 54 | Molecular Mechanism for Low pH Triggered Misfolding of the Human Prion Protein. <i>Biochemistry</i> , 2007, 46, 3045-3054. | 2.5 | 78 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Structural Properties of Prion Protein Protofibrils and Fibrils: An Experimental Assessment of Atomic Models. <i>Biochemistry</i> , 2006, 45, 15573-15582. | 2.5 | 67 |
| 56 | Local environmental effects on the structure of the prion protein. <i>Comptes Rendus - Biologies</i> , 2005, 328, 847-862. | 0.2 | 45 |
| 57 | Pauling and Corey's β -pleated sheet structure may define the prefibrillar amyloidogenic intermediate in amyloid disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 11622-11627. | 7.1 | 133 |
| 58 | From conversion to aggregation: Protofibril formation of the prion protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 2293-2298. | 7.1 | 293 |
| 59 | Diffusing and Colliding: The Atomic Level Folding/Unfolding Pathway of a Small Helical Protein. <i>Journal of Molecular Biology</i> , 2004, 341, 1109-1124. | 4.2 | 38 |
| 60 | Unifying features in protein-folding mechanisms. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 13286-13291. | 7.1 | 225 |